ClinicalTrials.gg
RecruitingNCT07007962LUNA 4Updated Nov 12, 2026

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

A Phase 3 interventional study of rilzabrutinib in Immune Thrombocytopenia, sponsored by Sanofi. Recruiting at 54 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 12, 2026First site in Norway29 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.

Planned enrollment
37th of 94
60 · median 42
Started
2025
with 11 others
Phase 3
32 of 110
6 open now
Primary completion
2027-11
later than 12 of 21 live
Registered
100th of 110
by date

Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 37th largest by planned enrollment of the 94 interventional ones that give a count, is one of 12 that started in 2025, is one of 32 in phase 3, reaches primary completion later than 12 of the 21 other live ones, and was the 100th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, or all of them as a file.
02

Study summary

This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.

03

Conditions studied

  • Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female participants aged 18 years and older with a documented diagnosis of primary ITP in the medical history
  • Participant received at least one course of therapy and had a history of response while on treatment
  • Participant has loss of response, relapse, or dependency

Key Exclusion Criteria:

  • Participants with Secondary ITP
  • Participants with Evans syndrome or history of myelodysplastic syndrome
  • Participants with history of lymphoma, leukemia, or any within the past 5 years except for non-melanoma skin malignancy.
  • Participants with history of solid organ transplant
  • Participants with history of coagulation or bleeding disorders other than ITP, including genetic conditions, other than ITP
  • Participant received advanced therapy for ITP or was splenectomized
  • Pregnancy or nursing The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    rilzabrutinib

    400 mg BID

    Drug: rilzabrutinib

Interventions

  • Pharmaceutical form:Tablet-Route of administration:Oral

    Also known as: SAR444671

06

What researchers measure

Primary outcomes

  1. Durable platelet response

    Defined as the percentage of participants able to achieve platelet counts ≥50 000/μL (or ≥30 000/μL and \<50 000/μL and at least double from baseline) for ≥50% of 6 biweekly scheduled platelet measurements and at least 4 non-missing, biweekly visits during the last 12 weeks of the primary analysis period (PAP) in absence of rescue therapy

    Time frame: Until Week 28

Secondary outcomes

  1. Overall platelet response

    Percentage of participants able to achieve 2 platelet counts at least 5 days apart of ≥50 000/μL (or ≥30 000/μL and \<50 000/μL and at least double from baseline) without rescue therapy in the 4 weeks prior to the first elevated platelet count

    Time frame: Until Week 28

  2. Duration of platelet response

    Cumulative number and proportion of non-missing weeks with platelet counts ≥50 000/μL (or ≥30 000/μL and \<50 000/μL and at least double from baseline) in absence of rescue therapy in the 4 weeks prior to the elevated platelet count in participants who achieve a response (single platelet count)

    Time frame: Until Week 28

  3. Change from baseline in the immune thrombocytopenia bleeding scale (IBLS) score at the end of week 28

    Time frame: Until Week 28

  4. Percentage of participants able to discontinue or reduce CS dose by at least 50% or to ≤5 mg/day (prednisone equivalent) from baseline at the end of week 28

    Time frame: Until Week 28

  5. Frequency and severity of treatment emergent adverse events (TEAEs, including serious adverse events [SAEs], bleeding TEAEs, adverse events of special interest [AESI] and adverse events leading to discontinuation)

    Time frame: Until Week 80

  6. Percentage of participants with potential clinical significant abnormal (PCSA)

    PCSA in physical examination, ECG, vital signs, and clinical laboratory test results: serum chemistry and hematology (except for platelet counts included in the primary efficacy endpoint)

    Time frame: Until Week 80

07

Study locations

54 of 54 sites recruiting
  • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) Site Number: 8400005
    Clovis, California 93611, United States
    Recruiting
  • University of Southern California (USC) Norris Comprehensive Cancer Center Site Number: 8400015
    Los Angeles, California 90033, United States
    Recruiting
  • The Lundquist Institute for Biomedical Innovation - Harbor-UCLA Medical Center Site Number: 8400017
    Torrance, California 90502-2006, United States
    Recruiting
  • MedStar Georgetown University Hospital Site Number: 8400014
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • Bleeding and Clotting Disorders Institute Site Number: 8400018
    Peoria, Illinois 61614, United States
    Recruiting
  • Tulane University Health Sciences Center - Tulane Avenue-Investigational Site Number: 8400011
    New Orleans, Louisiana 70112, United States
    Recruiting
  • Massachusetts General Hospital Site Number: 8400004
    Boston, Massachusetts 02114, United States
    Recruiting
  • Beth Israel Deaconess Medical Center Site Number: 8400019
    Boston, Massachusetts 02215, United States
    Recruiting
  • Mass General/North Shore Cancer Center Site Number: 8400020
    Danvers, Massachusetts 01923, United States
    Recruiting
  • University of Michigan Health - Michigan Medicine - University Hospital Site Number: 8400001
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • M Health Center for Bleeding and Clotting Disorders Site Number: 8400013
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • Mayo Clinic_Investigational Site Number: 8400009
    Rochester, Minnesota 55905, United States
    Recruiting
  • New York Oncology Hematology Site Number: 8400010
    Albany, New York 12208, United States
    Recruiting
  • Montefiore Medical Center-Investigational Site Number: 8400012
    The Bronx, New York 10467, United States
    Recruiting
  • Oregon Health & Science University - Knight Cancer Institute Site Number: 8400006
    Portland, Oregon 97239, United States
    Recruiting
  • East Carolina University Site Number: 8400003
    Greenville, South Carolina 27834, United States
    Recruiting
  • Community Cancer Trials of Utah Site Number: 8400002
    Ogden, Utah 84405, United States
    Recruiting
  • University of Washington Site Number: 8400008
    Seattle, Washington 98112, United States
    Recruiting
  • Investigational Site Number : 0400001
    Hanusch-Krankenhaus, 01140, Austria
    Recruiting
  • Investigational Site Number : 2030001
    Ostrava, 70852, Czechia
    Recruiting
  • Investigational Site Number : 2030002
    Prague, 128 00, Czechia
    Recruiting
  • Investigational Site Number : 2500005
    Antony, 92160, France
    Recruiting
  • Investigational Site Number : 2500003
    Créteil, 94000, France
    Recruiting
  • Investigational Site Number : 2500001
    Dijon, 21000, France
    Recruiting
  • Investigational Site Number : 2500002
    Pessac, 33604, France
    Recruiting
  • Investigational Site Number : 2500004
    Toulouse, 31059, France
    Recruiting
  • Investigational Site Number : 2760005
    Berlin, 13353, Germany
    Recruiting
  • Investigational Site Number : 2760001
    Dresden, 01307, Germany
    Recruiting
  • Investigational Site Number : 2760006
    Essen, 45147, Germany
    Recruiting
  • Investigational Site Number : 2760002
    Frankfurt am Main, 60596, Germany
    Recruiting
  • Investigational Site Number : 2760004
    Leipzig, 04103, Germany
    Recruiting
  • Investigational Site Number : 3480001
    Budapest, 01088, Hungary
    Recruiting
  • Investigational Site Number : 3480003
    Debrecen, 04032, Hungary
    Recruiting
  • Investigational Site Number : 3480002
    Kaposvár, 07400, Hungary
    Recruiting
  • Investigational Site Number : 3800002
    Meldola, 47014, Italy
    Recruiting
  • Investigational Site Number : 3800004
    Milan, 20162, Italy
    Recruiting
  • Investigational Site Number : 3800006
    Naples, 80131, Italy
    Recruiting
  • Investigational Site Number : 3800007
    Torino, 10126, Italy
    Recruiting
  • Investigational Site Number : 3800001
    Trieste, 34125, Italy
    Recruiting
  • Investigational Site Number : 3800003
    Vicenza, 36100, Italy
    Recruiting
  • Investigational Site Number : 5780001
    Grålum, 01714, Norway
    Recruiting
  • Investigational Site Number : 6160002
    Gdansk, 80-219, Poland
    Recruiting
  • Investigational Site Number : 6160001
    Lodz, 93-513, Poland
    Recruiting
  • Investigational Site Number : 6160003
    Skorzewo, 60-185, Poland
    Recruiting
  • Investigational Site Number : 6160004
    Słupsk, 76-200, Poland
    Recruiting
  • Investigational Site Number : 7240001
    Barcelona, 08003, Spain
    Recruiting
  • Investigational Site Number : 7240009
    Barcelona, 08035, Spain
    Recruiting
  • Investigational Site Number : 7240002
    Burgos, 09006, Spain
    Recruiting
  • Investigational Site Number : 7240007
    Madrid, 28007, Spain
    Recruiting
  • Investigational Site Number : 7240008
    Madrid, 28046, Spain
    Recruiting
  • Investigational Site Number : 7240005
    Murcia, 30008, Spain
    Recruiting
  • Investigational Site Number : 7240010
    Palma, 07120, Spain
    Recruiting
  • Investigational Site Number : 7240003
    San Cristóbal de La Laguna, 38320, Spain
    Recruiting
  • Investigational Site Number : 7240004
    Seville, 41013, Spain
    Recruiting
08

References and documents

Publications

  • Mjali A, Audia S, Miyakawa Y, Ghanima W. Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways. Expert Rev Hematol. 2026 Jul;19(7):685-696. doi: 10.1080/17474086.2026.2672113. Epub 2026 May 13. PubMed 42106923 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's planned 24 months is close to that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 6, 2025
StartActual
Oct 24, 2025
Primary completionEst.
Nov 5, 2027
CompletionEst.
Dec 30, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
29 sites added, 11 sites removed — first site in Norway
Show 29 added (15 United States, 4 Germany, 2 France, 2 Spain, 1 Austria, 1 Czechia, 1 Hungary, 1 Italy, 1 Norway, 1 Poland)
  • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) Site Number: 8400005 · Clovis, United States
  • University of Southern California (USC) Norris Comprehensive Cancer Center Site Number: 8400015 · Los Angeles, United States
  • The Lundquist Institute for Biomedical Innovation - Harbor-UCLA Medical Center Site Number: 8400017 · Torrance, United States
  • MedStar Georgetown University Hospital Site Number: 8400014 · Washington D.C., United States
  • Bleeding and Clotting Disorders Institute Site Number: 8400018 · Peoria, United States
  • Massachusetts General Hospital Site Number: 8400004 · Boston, United States
  • Beth Israel Deaconess Medical Center Site Number: 8400019 · Boston, United States
  • Mass General/North Shore Cancer Center Site Number: 8400020 · Danvers, United States
  • University of Michigan Health - Michigan Medicine - University Hospital Site Number: 8400001 · Ann Arbor, United States
  • M Health Center for Bleeding and Clotting Disorders Site Number: 8400013 · Minneapolis, United States
  • New York Oncology Hematology Site Number: 8400010 · Albany, United States
  • Oregon Health & Science University - Knight Cancer Institute Site Number: 8400006 · Portland, United States
  • East Carolina University Site Number: 8400003 · Greenville, United States
  • Community Cancer Trials of Utah Site Number: 8400002 · Ogden, United States
  • University of Washington Site Number: 8400008 · Seattle, United States
  • Investigational Site Number : 0400001 · Hanusch-Krankenhaus, Austria
  • Investigational Site Number : 2030001 · Ostrava, Czechia
  • Investigational Site Number : 2500005 · Antony, France
  • Investigational Site Number : 2500003 · Créteil, France
  • Investigational Site Number : 2760005 · Berlin, Germany
  • Investigational Site Number : 2760001 · Dresden, Germany
  • Investigational Site Number : 2760006 · Essen, Germany
  • Investigational Site Number : 2760002 · Frankfurt am Main, Germany
  • Investigational Site Number : 3480003 · Debrecen, Hungary
  • Investigational Site Number : 3800001 · Trieste, Italy
  • Investigational Site Number : 5780001 · Grålum, Norway
  • Investigational Site Number : 6160001 · Lodz, Poland
  • Investigational Site Number : 7240009 · Barcelona, Spain
  • Investigational Site Number : 7240010 · Palma, Spain
Show 11 removed
  • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) · Clovis, United States
  • University of Southern California (USC) · Los Angeles, United States
  • Massachusetts General Hospital Cancer Center · Boston, United States
  • Beth Israel Deaconess Medical Center · Boston, United States
  • Mass General Brigham Cancer Institute · Danvers, United States
  • University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001 · Ann Arbor, United States
  • New York Oncology Hematology-Investigational Site Number: 8400010 · Albany, United States
  • Oregon Health and Sciences University · Portland, United States
  • Community Cancer Trials of Utah-Investigational Site Number: 8400002 · Ogden, United States
  • Investigational Site Number : 0400001 · Vienna, Austria
  • Investigational Site Number: 2500003 · Créteil, France
Nov 12, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42106923 ↗
Nov 12, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPercentage of participants able to discontinue or reduce CS dose by at least 50% or to <≤5 mg/day (prednisone equivalent) from baseline at the end of week 28Time frame: Until Week 28
  • EditedFrequency and severity of treatment emergent adverse events (TEAEs, including serious adverse events [SAEs], bleeding TEAEs, adverse eventevents of special interest [AESI] and adverse events leading to discontinuation)Time frame: Until Week 80
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42106923 ↗
    29 sites added, 11 sites removed — first site in Norway
    Show 29 added (15 United States, 4 Germany, 2 France, 2 Spain, 1 Austria, 1 Czechia, 1 Hungary, 1 Italy, 1 Norway, 1 Poland)
    • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) Site Number: 8400005 · Clovis, United States
    • University of Southern California (USC) Norris Comprehensive Cancer Center Site Number: 8400015 · Los Angeles, United States
    • The Lundquist Institute for Biomedical Innovation - Harbor-UCLA Medical Center Site Number: 8400017 · Torrance, United States
    • MedStar Georgetown University Hospital Site Number: 8400014 · Washington D.C., United States
    • Bleeding and Clotting Disorders Institute Site Number: 8400018 · Peoria, United States
    • Massachusetts General Hospital Site Number: 8400004 · Boston, United States
    • Beth Israel Deaconess Medical Center Site Number: 8400019 · Boston, United States
    • Mass General/North Shore Cancer Center Site Number: 8400020 · Danvers, United States
    • University of Michigan Health - Michigan Medicine - University Hospital Site Number: 8400001 · Ann Arbor, United States
    • M Health Center for Bleeding and Clotting Disorders Site Number: 8400013 · Minneapolis, United States
    • New York Oncology Hematology Site Number: 8400010 · Albany, United States
    • Oregon Health & Science University - Knight Cancer Institute Site Number: 8400006 · Portland, United States
    • East Carolina University Site Number: 8400003 · Greenville, United States
    • Community Cancer Trials of Utah Site Number: 8400002 · Ogden, United States
    • University of Washington Site Number: 8400008 · Seattle, United States
    • Investigational Site Number : 0400001 · Hanusch-Krankenhaus, Austria
    • Investigational Site Number : 2030001 · Ostrava, Czechia
    • Investigational Site Number : 2500005 · Antony, France
    • Investigational Site Number : 2500003 · Créteil, France
    • Investigational Site Number : 2760005 · Berlin, Germany
    • Investigational Site Number : 2760001 · Dresden, Germany
    • Investigational Site Number : 2760006 · Essen, Germany
    • Investigational Site Number : 2760002 · Frankfurt am Main, Germany
    • Investigational Site Number : 3480003 · Debrecen, Hungary
    • Investigational Site Number : 3800001 · Trieste, Italy
    • Investigational Site Number : 5780001 · Grålum, Norway
    • Investigational Site Number : 6160001 · Lodz, Poland
    • Investigational Site Number : 7240009 · Barcelona, Spain
    • Investigational Site Number : 7240010 · Palma, Spain
    Show 11 removed
    • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) · Clovis, United States
    • University of Southern California (USC) · Los Angeles, United States
    • Massachusetts General Hospital Cancer Center · Boston, United States
    • Beth Israel Deaconess Medical Center · Boston, United States
    • Mass General Brigham Cancer Institute · Danvers, United States
    • University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001 · Ann Arbor, United States
    • New York Oncology Hematology-Investigational Site Number: 8400010 · Albany, United States
    • Oregon Health and Sciences University · Portland, United States
    • Community Cancer Trials of Utah-Investigational Site Number: 8400002 · Ogden, United States
    • Investigational Site Number : 0400001 · Vienna, Austria
    • Investigational Site Number: 2500003 · Créteil, France
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPercentage of participants able to discontinue or reduce CS dose by at least 50% or to <≤5 mg/day (prednisone equivalent) from baseline at the end of week 28Time frame: Until Week 28
    • EditedFrequency and severity of treatment emergent adverse events (TEAEs, including serious adverse events [SAEs], bleeding TEAEs, adverse eventevents of special interest [AESI] and adverse events leading to discontinuation)Time frame: Until Week 80
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07007962
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Oct 24, 2025
Primary completion
Nov 5, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion